



No: 111/CPC1 - PC

Disclosure: On the approval of the policy to enter into a contract between Central Pharmaceutical CPC1.JSC and the related party – OPC Pharmaceutical Joint Stock Company.

Hanoi, 10 January 2026

To: - State Securities Commission of Vietnam;
- Hanoi Stock Exchange.

Company: CENTRAL PHARMACEUTICAL CPC1.JSC

Stock code: DP1

Head office: No. 87 Nguyen Van Troi Street, Phuong Liet Ward, Hanoi

Phone: 0243. 8643306 Fax: 0243. 8641366

Type of Information Disclosure:

[X] Unusual 24h [] Upon Request [] Periodic [] Other

Content of Report and Information Disclosure:

Central Pharmaceutical CPC1.JSC hereby discloses Resolution of the Board of Directors No. 02/NQ-HĐQT dated 09 January 2026 on the approval of the policy to enter into a contract between Central Pharmaceutical CPC1.JSC and the related party - OPC Pharmaceutical Joint Stock Company.

This information was published on the Company’s website on 10 January 2025 at the following link: www.cpc1.com.vn – Shareholders – Information Disclosure.

Our company commits that the reported and disclosed information above is truthful, and we take full legal responsibility for the content of the reported and disclosed information.

Sincerely,

Recipients:

- As stated above;
- Chairwoman of the BOD (for report);
- Board of Management;
- Related units;
- Archives: Clerical, Legal.

AUTHORIZED PERSON FOR INFORMATION DISCLOSURE GENERAL DIRECTOR



Ta Van Dung

Attachments:

- Resolution No. 02/NQ-HĐQT – CPC1



RESOLUTION

**On the approval of the policy to enter into a contract between
Central Pharmaceutical CPC1.JSC and the related party –
OPC Pharmaceutical Joint Stock Company**

**BOARD OF DIRECTORS
CENTRAL PHARMACEUTICAL CPC1.JSC**

Pursuant to the Law on Enterprises No. 59/2020/QH14 issued on 17 June 2020, as amended and supplemented by Law No. 03/2022/QH15 dated 10 January 2022 and the Law No. 76/2025/QH15 dated 17 June 2025;

Pursuant to the Law on Securities dated 26 November 2019; Law No. 56/2024/QH15 amended 24 November 2024, supplementing a number of provisions of the Law on Securities and other related laws;

Pursuant to the Fifth Amendment of the Charter of Central Pharmaceutical CPC1.JSC dated 11 April 2024;

Pursuant to Submission No. 2609/TTr-CPC1 dated 26 December 2025 of the General Director to the Board of Directors regarding the approval of the policy to enter into a contract between Central Pharmaceutical CPC1.JSC and the related party – OPC Pharmaceutical Joint Stock Company;

Pursuant to the Minutes summarizing the opinions of the Board of Directors No. 01/BBHĐQT - CPC1 dated 09 January 2026.



RESOLVES:

Article 1. Approval for the policy to enter into a contract between Central Pharmaceutical CPC1.JSC (hereinafter referred to as CPC1) and the related party - OPC Pharmaceutical Joint Stock Company (hereinafter referred to as OPC) as proposed in Submission No. 2609/TTr - CPC1 dated 26 December 2025 of the General Director, with the specific contents as follows:

- Scope of distribution: CPC1 shall be the exclusive distributor of OPC's products in the ETC market through participation in bidding or direct procurement based on bidding results (direct purchasing), in accordance with applicable laws, in 15 provinces in Northern Vietnam (from Ninh Binh northwards).

- Supply role: OPC shall act as the supplier of goods to CPC1 for the purpose of enabling CPC1 to exercise its distribution rights in the above-mentioned market area.

- Goods: OPC shall supply to CPC1 goods that are manufactured and lawfully distributed by OPC.

- Quantity: The quantity of goods shall be determined based on CPC1's actual ordering demand each time.

- Bid price:

- Selling price: [REDACTED]

- Term of the Contract: The Contract shall take effect from the date of signing, 09 January 2026, and remain effective until 31 December 2026, and shall continue to remain in force until both parties complete the final settlement of all goods and any arising payables and receivables.

- Transaction value: The total value of transactions arising between CPC1 and OPC during the contract term (12 months) shall always be ensured to be less than 20% of the total assets recorded in the Company's most recent audited financial statements.

Article 2. Authorization for the General Director to decide on the contents and detailed terms, organize the negotiation, execution, and implementation of the contract in accordance with the Company's regulations and the provisions of applicable law, ensuring the lawful rights and interests of the Company.

Article 3. This Resolution shall take effect from the date of signing.

Members of the Board of Directors, the Board of Management, the Company's departments, and relevant parties shall be responsible for implementing this Resolution in accordance with the Company's Charter and the provisions of law.

Recipients:

- As stated in Article 3;
- Audit Committee;
- Archives: Clerical, Secretary.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**



Han Thi Khanh Vinh

